---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-307898"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2022-12-19T23:59:59+00:00"
generated_at: "2026-06-21T02:33:32.400505+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Atara gets EC approval for Ebvallo in EBV+ PTLD; board changes announced

## Summary
- EC granted marketing authorization for Ebvallo (tabelecleucel) as monotherapy for relapsed/refractory EBV+ PTLD in adult/pediatric patients 2+ years.
- Approval applies to all 27 EU member states plus Iceland, Norway, and Liechtenstein.
- Directors Ronald C. Renaud and Roy Baynes resigned effective Dec 19, 2022; Carol D. Gallagher appointed Chair.
- Board size reduced from ten to eight directors.

## SEC filing metadata
- accession: 0001193125-22-307898
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2022-12-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312522307898/0001193125-22-307898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312522307898/d437946d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-307898
- JSON: https://secwatch.observer/filing/0001193125-22-307898.json
- Plain text: https://secwatch.observer/filing/0001193125-22-307898.txt

## Key facts
- Executive change
  Carol D. Gallagher was appointed as Chair of the Board at Atara Biotherapeutics, Inc..
  - Action: appointed
  - Role: Chair of the Board
  source text: In addition, effective as of December 19, 2022, the Board appointed Carol D. Gallagher, Pharm D., an independent member of the Board, to succeed Mr. Renaud as Chair of the Board and, in accordance with Section 16 of the Company’s Second Amended and Restated Bylaws, reduced the number of directors on the Board from ten to eight directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000119312522307898/0001193125-22-307898-index.htm
- Executive change
  Roy Baynes resigned as Director at Atara Biotherapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Also on December 16, 2022, Roy Baynes notified the Company of his resignation from the Board, effective as of December 19, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000119312522307898/0001193125-22-307898-index.htm
- Executive change
  Ronald C. Renaud resigned as Director at Atara Biotherapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On December 16, 2022, Ronald C. Renaud notified Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), of his resignation from the Board of Directors of the Company (the “Board”), effective as of December 19, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000119312522307898/0001193125-22-307898-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.